Previous close | 21.72 |
Open | 21.70 |
Bid | 22.11 x 300 |
Ask | 22.16 x 200 |
Day's range | 21.58 - 22.35 |
52-week range | 19.52 - 30.52 |
Volume | |
Avg. volume | 632,447 |
Market cap | 1.664B |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.02 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 31.67 |
SOUTH SAN FRANCISCO, Calif., February 27, 2024--Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
Veracyte ( NASDAQ:VCYT ) Full Year 2023 Results Key Financial Results Revenue: US$361.1m (up 22% from FY 2022). Net...
Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript February 22, 2024 Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.07. Veracyte, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you […]